Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Aug 26, 2026
Why Is Spyre Therapeutics (SYRE) Stock Down -14.74% Today?

Why Is Spyre Therapeutics (SYRE) Stock Down -14.74% Today?

Key Takeaways

  • Shares of SYRE plunged 14.74% in Tuesday's session, falling from a prior close of $107.36 to $91.54.
  • Primary catalyst: Topline Phase 2 SKYWAY-RA results for SPY072 in rheumatoid arthritis showed statistically significant but commercially underwhelming efficacy, prompting the company to abandon SPY072 as a standalone RA monotherapy.
  • Secondary driver: The efficacy magnitude fell short of Spyre's internal bar, raising questions about the broader TL1A franchise's competitive positioning in rheumatology.
  • Broader context: The sell-off reflects a pattern of negative post-clinical-trial reactions for Spyre, with four of the last five trial readouts producing negative next-day price moves.
  • What traders are watching next: Upcoming SKYLINE Part A ulcerative colitis data for SPY003 in September 2026 and SKYWAY PsA/axSpA readouts in Q4 2026.

Opening Summary

Spyre Therapeutics, Inc. (SYRE), a clinical-stage biotechnology company developing next-generation antibody therapies for inflammatory bowel disease (IBD) and rheumatic diseases, saw its stock crater on Tuesday, August 26, 2026. Shares tumbled 14.74% to $91.54, down from the prior session's close of $107.36. The sharp decline came in direct response to topline results from the rheumatoid arthritis (RA) sub-study of the Phase 2 SKYWAY basket trial evaluating SPY072, the company's investigational anti-TL1A antibody. While the drug achieved statistical significance on several endpoints, the magnitude of effect failed to meet Spyre's internal threshold for prioritizing monotherapy development in RA — a decision that spooked investors and triggered a broad reassessment of the company's near-term pipeline value.

SKYWAY-RA Results: A Statistically Positive but Strategically Disappointing Readout

The market reaction to SYRE was driven almost entirely by the SKYWAY-RA data. Low-dose SPY072 met the primary endpoint, showing a statistically significant improvement in DAS28-CRP versus placebo at Week 12 (-1.9 vs. -1.3, p<0.05). High-dose SPY072 demonstrated nominally significant ACR20 responses (63% vs. 43% placebo), while low-dose showed nominally significant ACR50 improvements (38% vs. 19% placebo). Safety was clean, with adverse event rates comparable to placebo (27% active vs. 36% placebo) and no drug-related serious adverse events.

However, the headline numbers masked a deeper problem: the absolute efficacy deltas were modest. ACR70 responses — the deepest measure of clinical remission — reached only 13% on high dose versus 2% on placebo, a gap that failed to convince Spyre's leadership that SPY072 could compete as a best-in-class RA monotherapy. CEO Cameron Turtle acknowledged the data "did not meet the Company's internal bar to prioritize advancement of SPY072 in RA," effectively shelving the program's standalone path in the indication. For a company whose valuation has been built on the promise of multiple blockbuster autoimmune readouts, removing a major monotherapy opportunity from the near-term narrative was enough to trigger a double-digit sell-off.

Pipeline Repricing and the TL1A Competitive Landscape

Beyond the immediate RA disappointment, Tuesday's decline reflects a broader repricing of Spyre's TL1A franchise. The company has positioned its long-acting anti-TL1A antibodies — SPY002 and SPY072 — as potential best-in-class agents across IBD, hidradenitis suppurativa (HS), and rheumatic diseases. The SKYWAY-RA results, while providing proof-of-mechanism for TL1A inhibition in RA, did not demonstrate the kind of differentiated efficacy that would justify prioritizing the program over competitors in an increasingly crowded immunology space.

Investors are now recalibrating expectations for the remaining SKYWAY sub-studies in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA), both expected in Q4 2026. If the RA data is any guide, those readouts may also produce statistically significant but commercially marginal results, further compressing the company's standalone monotherapy optionality. The market's reaction suggests growing skepticism that Spyre's TL1A platform can deliver the magnitude of effect needed to disrupt established treatment paradigms in rheumatology.

Market Context and Trading Activity

Trading volume in SYRE was elevated relative to its 10-day average of approximately 0.83 million shares, with the stock opening sharply lower at $92.00 and trading as low as $90.60 before settling near $91.54. The move diverged from the broader biotechnology sector, which traded relatively flat on the day, confirming that the decline was company-specific rather than macro-driven. The stock broke decisively below its 50-day moving average and tested levels not seen since early August, signaling a technical breakdown that could invite further selling pressure in the near term.

The after-hours session on August 25 had already foreshadowed the rout, with shares falling as much as 14% in extended trading immediately following the press release. Tuesday's regular-session decline confirmed and extended those losses, with the stock now down more than 17% from its 52-week high of $110.18 set just days earlier on August 19.

What Comes Next for SYRE

Spyre's near-term narrative now hinges on a series of high-stakes clinical readouts over the next 12 to 18 months. The most immediate catalyst is the SKYLINE Part A ulcerative colitis data for SPY003, expected in September 2026. That readout will test whether Spyre's next-generation anti-IL-23 antibody can deliver the kind of differentiated efficacy in IBD that SPY072 failed to show in RA. Following that, the SKYWAY PsA and axSpA sub-studies in Q4 2026 will determine whether the TL1A platform has any standalone value in rheumatology at all.

Longer term, the company is pivoting toward combination strategies, including the recently launched SKYLIGHT Phase 2 trial of SPY072 plus an anti-IL-17A/F antibody in hidradenitis suppurativa, with data expected in late 2027 or early 2028. While Spyre ended Q2 2026 with $1.1 billion in cash — providing runway into the second half of 2029 — the market's patience for incremental, statistically significant but commercially underwhelming data is clearly wearing thin. Analysts remain broadly bullish with a consensus Strong Buy rating and an average price target of $124.71, but Tuesday's sell-off underscores the widening gap between sell-side optimism and investor skepticism about the company's ability to deliver a truly differentiated product.

Trending AI Robots

For traders seeking systematic approaches to navigate volatile biotech names like SYRE, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots. Tickeron hosts hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. Bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing users to explore automated approaches tailored to different risk profiles and market environments. Explore the Trending AI Robots page to see which strategies are currently leading the market.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SYRE

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


SYRE in downward trend: price dove below 50-day moving average on August 26, 2026

SYRE moved below its 50-day moving average on August 26, 2026 date and that indicates a change from an upward trend to a downward trend. In 40 of 44 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 58 cases where SYRE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.

The 10-day moving average for SYRE crossed bearishly below the 50-day moving average on September 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYRE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SYRE's RSI Indicator exited the oversold zone, 30 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.

The Momentum Indicator moved above the 0 level on September 14, 2026. You may want to consider a long position or call options on SYRE as a result. In 67 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.

The Moving Average Convergence Divergence (MACD) for SYRE just turned positive on September 17, 2026. Looking at past instances where SYRE's MACD turned positive, the stock continued to rise in 34 of 40 cases over the following month. The odds of a continued upward trend are 85%.

Following a +1.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where SYRE advanced for three days, in 255 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.

SYRE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 156 of 168 cases where SYRE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. SYRE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.333) is normal, around the industry mean (25.929). P/E Ratio (1.716) is within average values for comparable stocks, (40.079). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.178). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (526.316) is also within normal values, averaging (437.043).

The Tickeron PE Growth Rating for this company is 73 (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SYRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Nektar Therapeutics (NASDAQ:NKTR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.2B. The market cap for tickers in the group ranges from 58 to 128.84B. VRTX holds the highest valuation in this group at 128.84B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 2%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was 7%. NRSN experienced the highest price growth at 1,794%, while LGVN experienced the biggest fall at -66%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 108%. For the same stocks of the Industry, the average monthly volume growth was 48% and the average quarterly volume growth was -48%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 78
Price Growth Rating: 59
SMR Rating: 93
Profit Risk Rating: 92
Seasonality Score: -12 (-100 ... +100)
View a ticker or compare two or three
SYRE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a biopharmaceutical company

Industry Biotechnology

Profile
Details
Industry
Pharmaceuticals Major
Address
221 Crescent Street
Phone
+1 617 651-5940
Employees
102
Web
https://www.spyre.com
Interact to see
Advertisement
Shares of ALDX are down about 73.02% in premarket trading, plunging from a prior close near 4.13 dollars to roughly 1.11 dollars after a major regulatory setback. The collapse follows fresh confirmation that the U.S. Food and Drug Administration has again declined to approve reproxalap for dry eye disease, issuing another Complete Response Letter that questions efficacy.
Shares of MVST are down about 25% in premarket trading today compared with the prior close. The slide follows a sharp reassessment of the company’s outlook as investors react to new information and recent volatility in high‑beta battery and EV names.
Solaris Energy Infrastructure’s stock SEI jumped roughly 13% in today’s session, extending a sharp recent rebound from early-March lows. The move is driven by ongoing post-earnings momentum after strong Q4 and full‑year 2025 results and raised guidance highlighted rapid growth in its power solutions business.
Shares of LMND are trading approximately +10% higher intraday on Tuesday, March 17, 2026, rising from a prior close of $57.74 to around $63.51. Primary catalyst: Morgan Stanley upgraded LMND to an 'Overweight' rating and raised its price target to $85 from $80.
Shares of ICHR surged approximately +15% intraday on Tuesday, March 17, 2026, trading near $48.98 versus a prior closing price of $42.59. The primary catalyst is a high-profile analyst upgrade by Stifel, with analyst Brian Chin upgrading the stock to Buy citing improved cyclical strength and conviction in the company's revenue and margin trajectory.
NBIS shares are down approximately 10.00% in Tuesday's session, falling from a prior close of $129.85 to around $116.87. The primary catalyst is Nebius Group's pre-market announcement of a proposed $3.75 billion convertible senior notes offering, sparking dilution concerns.
TME shares fell over 20% today, with the stock sliding from the mid‑$15s toward the low‑$13s in the wake of its Q4 2025 report and earnings call, extending a pre‑market drop of roughly 12–13%.
HUYA shares fell over 11% today, dropping from the mid‑$3 range toward the low‑$3s following the company’s Q4 2025 earnings release before the U.S. market open. Q4 total net revenues rose about 16% year over year to roughly CNY 1.74 billion, with full‑year 2025 revenues up around 7% to CNY 6.5 billion, but the market had already priced in a rebound after a difficult 2024.​
CWCO fell over 9% today, trading around the low‑$31 range versus recent levels in the mid‑$30s to near $39, as the market reacted negatively to Q4 2025 results and forward commentary. Full‑year 2025 results showed stable earnings and dividend growth but a roughly 9% decline in services revenue to about $46.3 million, reflecting a slowdown in project‑based construction work.
SMTC shares dropped over 8% today after the company reported Q4 results that met or modestly beat Street estimates but showed the slowest year‑over‑year revenue growth in several quarters, at about 9.3% to roughly $274–275 million.
AXTI shares slipped more than 6% today, reversing part of a powerful rally that had recently driven the stock to a 52‑week high above $47 and more than doubled its price year‑to‑date. Q4 2025 revenue of about $23.0 million missed consensus by roughly $1.2 million and fell 8–18% year over year and sequentially, while the company posted another GAAP net loss of around $3.5 million (–$0.08 per share).
Shares of SailPoint, Inc. (SAIL) are tumbling approximately 12% in premarket trading on March 18, 2026, after the company released its fiscal fourth-quarter and full-year 2026 results before the market opened. While Q4 revenue came in slightly above consensus at $295 million (+23% year-over-year), investors were rattled by disappointing forward guidance for fiscal 2027.
Shares of KC surged approximately +17% in premarket trading on March 18, 2026, from a prior close of $13.12 to approximately $15.35. The primary catalyst is Kingsoft Cloud's release of its unaudited Q4 and full-year 2025 financial results before the U.S. market open, which appear to have significantly exceeded analyst expectations.
AngloGold Ashanti (AU) shares tumbled approximately 7% in premarket trading on March 18, 2026, extending a multi-week downtrend that has erased nearly 20% of the stock's value since late January highs. The primary catalyst driving the decline is persistent investor concern over AngloGold's lowered 2026 production guidance, with the company projecting gold output of 2.80–3.17 million ounces — a roughly 3% decline from its 2025 production of 3.1 million ounces.
AAOI shares surged approximately 10.90% in premarket trading on March 18, 2026, rising from a prior close of $86.33 to $95.74. The primary catalyst is strong positive sentiment generated at OFC 2026 — the Optical Fiber Communications Conference and Exhibition — where Applied Optoelectronics unveiled breakthrough laser and transceiver technology for next-generation AI data center infrastructure.
LITE shares surged approximately +12% in early Wednesday trading on March 18, 2026, with the stock changing hands near $727 compared to a prior session close of $649.56. The primary near-term catalyst is Lumentum's S&P 500 index inclusion, effective March 23, 2026, triggering front-running by institutional investors and mandatory buying by passive index funds.
Shares of New Era Energy & Digital, Inc. (NUAI) are trading down approximately 17% during today's session, with the prior close sitting at $5.56. The decline follows the company's March 17 business update conference call and webcast, held after market hours, during which management discussed the recently filed fiscal year 2025 annual report (Form 10-K).
Shares of Regencell Bioscience Holdings (RGC) are up approximately +16% intraday on March 18, 2026, trading at $26.56 against a prior close of $22.97. No single company-specific press release is driving today's move; the rally is primarily fueled by retail-driven momentum and short squeeze mechanics.
A jump in the Producer Price Index from 0.3% to around 0.7% month‑over‑month signals that wholesale inflation is re‑accelerating, delaying Fed rate‑cut hopes and reviving the “higher for longer” rates narrative.business. Likely winners in this environment include energy and commodity producers (XOM, CVX, TTE, COP), inflation‑resilient financials (JPM, BAC), and real‑asset plays like pipelines and infrastructure, which can pass through higher prices; ETFs like XLE, XOP, XLF, DBA, GLD offer diversified exposure.
BGSI fell more than 11% today, pulling back from recent levels around the high‑$150s as investors reassessed the risk‑reward following the Q4 2025 print and major U.S. expansion plans. Full‑year 2025 sales rose 2.4% to US$3.14 billion, but same‑store sales declined 0.2%, while reported net earnings fell 25% to US$18.4 million due to US$22.6 million in acquisition and transformation costs.